Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

GlucoTrack, Inc.

GCTKNASDAQEQUITYCurrent

Annual Report

Filed Mar 31, 2023Accepted Mar 31, 2023, 4:45 PM EDTCIK 1506983Accession 0001493152-23-010356
Share

Company context

The Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM”).

Current securities

Historical securities (1)

Recent company filings

  1. 424B5 filingSep 24, 2026
  2. Entry into a Material Definitive Agreement · Regulation FD DisclosureSep 24, 2026
  3. 425 filingSep 23, 2026
  4. Regulation FD DisclosureSep 23, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 18, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗